Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.43 |
| ▸ | HTR3B | O95264 | 1/20 | 0.43 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.43 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 8/20 | 0.41 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.39 |
| ▸ | NPFFR2 | Q9Y5X5 | 3/20 | 0.38 |
| ▸ | NPFFR1 | Q9GZQ6 | 2/20 | 0.38 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21776816 | 0.83 | KIF11 (0.40) | NOTUMTRPV4 | |
| SCHEMBL31038840 | 0.83 | KIF11 (0.40) | NOTUMTRPV4 | |
| SCHEMBL14656234 | 0.81 | AR (0.49) | PYCR1IDO1KDR | |
| SCHEMBL2520644 | 0.80 | KDR (0.51) | PYCR1IDO1HTR3EHTR3BHTR3A | |
| SCHEMBL16961215 | 0.80 | IDO1 (0.43) | PYCR1IDO1HTR3EHTR3BHTR3A | |
| SCHEMBL628094 | 0.80 | TRPV4 (0.57) | IDO1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL3457978 | 0.80 | IDO1 (0.43) | PYCR1IDO1HTR3EHTR3BHTR3A | |
| SCHEMBL4927725 | 0.78 | KIF11 (0.41) | NOTUMTRPV4SLC22A12 | |
| SCHEMBL30967278 | 0.78 | KIF11 (0.41) | NOTUMTRPV4SLC22A12 | |
| SCHEMBL9793597 | 0.78 | AR (0.39) | TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3843844-B1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2024-08-28 | — | — | EP | disclosed |
| US-11634391-B2 | Compounds which are inhibitors of Notum | UCL BUSINESS LTD (GB) | 2023-04-25 | — | — | US | disclosed |
| EP-3843844-A1 | COMPOUNDS | UCL Business Ltd (GB) | 2021-07-07 | — | — | EP | disclosed |
| US-20210171475-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2021-06-10 | — | — | US | disclosed |
| US-20210171475-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2021-06-10 | — | — | US | disclosed |
| WO-2020043866-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2020-03-05 | — | — | WO | disclosed |
| WO-2020043866-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2020-03-05 | — | — | WO | disclosed |
| CN-1791592-B | Immunosuppressant compounds and compositions | IRM LLC | 2012-07-04 | — | — | CN | disclosed |
| US-7750021-B2 | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2010-07-06 | — | — | US | disclosed |
| US-20090131400-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2009-05-21 | — | — | US | disclosed |
| US-7417065-B2 | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2008-08-26 | — | — | US | disclosed |
| CN-1791592-A | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2006-06-21 | — | — | CN | disclosed |
| EP-1628967-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2006-03-01 | — | — | EP | disclosed |
| US-20050014725-A1 | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2005-01-20 | — | — | US | disclosed |
| WO-2005000833-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM, LLC (BM) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634391-B2 | Compounds which are inhibitors of Notum | NOTUM, GOT2, GOT1 | PYCR1 1962/4885IDO1 2743/4885HTR3E 4752/4885 |
| US-20050014725-A1 | Immunosuppressant compounds and compositions | ICOS, EDNRA, NFATC1 | PYCR1 480/4885IDO1 28/4885HTR3E 2545/4885 |
| US-20090131400-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | ICOS, EDNRA, NFATC1 | PYCR1 480/4885IDO1 28/4885HTR3E 2545/4885 |
| US-20210171475-A1 | COMPOUNDS | GOT2, GOT1, OAT | PYCR1 1646/4885IDO1 4116/4885HTR3E 3699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.